Venus Remedies: Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets
Venus Remedies (VENUSREM) filed a disclosure titled "Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets". The company is valued at about ₹2,206 crore.
What happened
Venus Remedies (VENUSREM) filed a disclosure with the exchanges on 16 October 2026 at 02:55 PM titled "Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets".
Company snapshot
Venus Remedies is a small-cap company, with a market value of about ₹2,206 crore.
The stock last traded at ₹1,650, against a 52-week range of ₹432.1–₹2,044.3 (19.3% below the high).
Before this filing the shares had moved +1.7% over the month and −12.1% over three months. Average daily turnover over the last 20 sessions was about ₹5.15 crore.
Promoters held 41.76% at the end of Q1 FY27. Foreign institutions owned 2.92% and domestic institutions 0.89%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 132 | 9.6 | 7.18 |
| Q2 FY26 | 193 | 20.1 | 15.06 |
| Q3 FY26 | 180 | 25.6 | 19.14 |
| Q4 FY26 | 259 | 47.5 | 35.53 |
| Q1 FY27 | 179 | 23 | 17.18 |
What history shows
BCEIE's records show 9 previous corporate update filings from the company since May 2026.
After those filings, the stock gained 0.3% on average the next trading day and was up 3.2% on average after five days (7 filings with price data).
Market-wide, 247 corporate update filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 40% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 30 Sept 2026 | As per file enclosed. | −1.0% | — |
| 30 Sept 2026 | 'Intimation regarding change in Corporate Identification Number… | −1.0% | — |
| 8 Sept 2026 | As per the pdf enclosed. | −1.1% | −8.0% |
| 7 Sept 2026 | Corporate update | −1.1% | −8.0% |
| 20 Jul 2026 | Corporate update | −0.4% | −9.6% |
What to watch
- 26 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Venus Remedies (VENUSREM.NS) Falls 5% to ₹1,681 as Pharma Stock Retreats Toward ₹1,597 Support - Factor Timing
- Venus Remedies Lower Circuit Today: Price, Data and Peers
- Venus Remedies VENUSREM Q2 FY27 Regulation 74(5) Compliance
- Venus Remedies secures five marketing authorisations across global markets
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.